Volume 2, Issue 3, September 2020, Pages 101 - 108
Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
Uttam K. Rao, Brian G. Engelhardt*
Department of Medicine, Vanderbilt University Medical Center, Medical Center Drive, Nashville, TN, USA
*Corresponding author. Tel.: 615-936-0381, Fax: 615-936-1812. Email: firstname.lastname@example.org
Brian G. Engelhardt
Received 20 March 2020, Accepted 4 May 2020, Available Online 21 May 2020.
- 10.2991/chi.d.200506.002How to use a DOI?
- ST2; IL-33; PTDM
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is characterized by immune dysregulation that can negatively impact transplant outcomes. This review will discuss the biology of IL-33/ST2 in acute GVHD and PTDM development, and how this cytokine axis could be leveraged for predicting and treating immuno-metabolic complications after transplant.
- © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Uttam K. Rao AU - Brian G. Engelhardt PY - 2020 DA - 2020/05/21 TI - Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2) JO - Clinical Hematology International SP - 101 EP - 108 VL - 2 IS - 3 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.200506.002 DO - 10.2991/chi.d.200506.002 ID - Rao2020 ER -